ProBio and UCI Therapeutics Sign a Strategic Cooperation MOU for Comprehensive Collaboration in Gene Delivery Technologies, Including Viral and Non-Viral Approaches

On September 04, 2024, ProBio, A global biologics CDMO, and UCI Therapeutics, an innovative new drug developer, announced that they had entered into a strategic cooperation MOU focused on advancing NK cell gene introduction technology. Through this MOU, ProBio and UCI Therapeutics have agreed to strengthen their collaboration in both viral and non-viral methods.

Under this agreement, both companies will work together to advance and optimize various gene introduction technologies for NK cells, which present significant challenges for modification and commercialization compared to other cell types. The collaboration will encompass the full spectrum of process development, research, and manufacturing services to support future pipeline applications. Additionally, the contract manufacturing agreement for the virus used in UCI Therapeutics' leading pipeline, UCI-101, was completed last month.

ProBio CEO Dr. Li Chen, stated “We are pleased to partner with UCI Therapeutics in this strategic collaboration. By leveraging our advanced virus platform, we aim to unlock new possibilities and accelerate the development of NK cell therapies. This partnership combines our expertise and sets the stage for groundbreaking advancements in the field, offering significant opportunities for innovation and growth in NK cell therapy.”

SuYeong Jeong of UCI Therapeutics, said “Through collaboration with ProBio, we want to make sure that gene introduction technologies, which are obstacles in the development of CAR-NK therapies, are reliably applied from development through to commercialization. We hope this will enable rapid commercialization and position us as a leading group in this field.”

About UCI Therapeutics – CAR-NK Therapy Developer

UCI Therapeutics, established in 2020, is a biotechnology venture focused on developing CAR-NK cell therapies based on gene introduction and NK cell engineering technologies. CAR-NK, a next-generation immune oncology cell therapy, combines CAR (chimeric antigen receptor) and NK (natural killer) cells to specifically target cancer cells. UCI Therapeutics differentiates itself with two key strategies: the development of bispecific CARs and the proprietary ‘CellTaCT’ platform, each addressing different aspects of therapeutic efficacy and overcoming the limitations of conventional combination therapies.

www.uci-therapeutics.com

About ProBio

ProBio, offers end-to-end CDMO services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in CGT, antibody and recombinant protein drug, aiming to accelerate drug development for customers. ProBio has established companies in the United States, the Netherlands, South Korea, and China and other regions to serve global customers, and has helped customers in the United States, Europe, Asia Pacific and other regions obtain more than 90 IND approvals since October 2017.

www.probiocdmo.com